About Neurodegenerative Disease Research, Inc.
Funding research that directly benefits ALS patients
Neurodegenerative Disease Research, Inc. is a not-for-profit organization that was formed with a mission to provide funding to researchers with an emphasis to identify and validate biomarkers for determining drug effectiveness in neurodegenerative diseases and facilitate pathology-based treatments to ALS patients. NDR supports open access to all findings via peer-reviewed publications.
NDR funded projects to date include the following:
+ Identifying markers for stressed tissue from adipose-derived stem cells
+ Investigating immune checkpoint cell signaling, in vitro analysis of perivascular stem cell repair of cell damage
+ Evaluating cytokine responses of treated peripheral blood mononuclear cells
+ Studies using SOD1 mouse models of ALS
+ Evaluating the components of conditioned media from various sources
+ Development of secretome as an ALS treatment
+ Modification of therapeutic molecules to increase effectiveness and decrease toxicity in ALS patients
+ Use of DNA and RNA analyses that define ALS phenotypes and metabolomic studies including metabolomics and miRNA studies
NDR works with researchers who demonstrate out-of-the-box approaches to identifying ALS biomarkers, ALS disease progression, and treatments that target the cause of ALS.
NDR understands that these novel approaches to research offer the most promise to developing treatments that directly improve patient quality of life.
For ALS Patients
NDR is funding research that identifies biomarkers, the key indicators of where a patient falls within the ALS spectrum as well as research into identifying the stages of disease progression.
Understanding this information is key to treating the root causes of ALS.